Novo Nordisk shared that its clinical trial of CagriSema, a combination injection for overweight people with type II diabetes, resulted in a 15.6% body weight reduction compared to the drugs dosed individually.
https://www.pharmalive.com/wp-content/uploads/2021/11/Novo-Nordisk-Snaps-Up-Partner-Dicerna-for-3.3-Billion-BioSpace-11-18-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-23 11:09:112022-08-23 12:12:19Novo Nordisk combo bests monotherapies in type 2 diabetes weight loss
